A B S T R A C T To assess the role ofcirculating immune complexes in the pathogenesis of acute rejection, sera were measured for such complexes by the 125I-Clq binding assay in 45 normal subjects, 24 allografted patients undergoing acute rejection, and in 11 allografted patients in a quiescent phase. Increased Clqbinding activity (Clq-BA) was detected in 14 patients with acute rejection, 9 of whom had renal biopsies showing fibrin deposition in the vasculature together with cellular infiltrates in the tubulo-interstitial structures; renal histology was not available in the other 5 patients. The other 10 patients with acute rejection, whose biopsies showed only cellular infiltrates, and the 11 patients in a quiescent phase posttransplantation did not have increased levels of serum Clq-BA.
globulin, and (or) less frequently, of complement in the glomeruli or the tubular basement membranes.
The findings suggest that circulating immune complexes may mediate the type of acute rejection characterized by fibrin deposition in the kidney. The role of circulating immune complexes arising from the recipient's original kidney disease could be excluded in 10 patients with humoral rejection, inasmuch as the underlying renal pathology was of a "nonimmunologic" nature; this was corroborated by sequential stuLdies in six patients in whom circulating immune complexes could not be demonstrated before rejection. The participation of administered antilymphocyte globulin (ALG) as an antigen also appears to be excluded in four patients, two who were not given ALG, and in two of whom episodes of rejection occurred unrelated temporally to ALG administration.
does not define the relationship of such complexes to the rejection phenomena (5 The histopathologic changes were assessed semiquantitatively by two observers independently, and without knowledge of the results of the assay for circulating immune complexes. Particular attention was paid to the presence of fibrin deposition in the microvasculature.
Immunofluorescence microscopy. In a few cases, a portion of renal biopsy material was used for immunofluorescence studies, employing a previously described technique (6) . The antisera were directed against IgG (y-chain), IgA (a-chain), IgM (,u-chain), /81C globulin, and fibrinogen. Each antiserum gave a single precipitin arc when tested by immunoelectrophoresis against normal human serum. Antisera were conjugated with fluorescein isothiocyanate (7) , and a single layering technique was used. Appropriate blocking experiments were also performed.
Isolation and labeling of Clq
Clq was isolated from human serum by the method of Yonemasu and Stroud (8) . The purity of the preparation was established by the demonstration of a single precipitin line on double immunodiffusion against a highly polyvalent goat antiserum to whole human serum. There was no evidence of contamination with IgG, IgA, or IgM by radial immunodiffusion using monospecific antibody to these proteins. The isolated protein was labeled with 125I (Radiochemical Centre, Amersham, England) according to a modified lactoperoxidase technique (9) , and the specific radioactivity was 0.08-0.2 IuCi/,ug Clq. The labeled material produced a single peak of radioactivity by cellulose acetate electrophoretic analysis, and by sucrose density gradient analysis.
The '25I-Clq was stored in 0.2-ml aliquots at -70°C until used. Immediately before use, the preparation was rapidly thawed in a 370C water bath and centrifuged at 25,000 g for 30 min to remove aggregates.
Detection of immune complexes by Clq binding assay
The method for detection of circulating immune complexes was the assay described by Nydegger et al. (10) with slight modification. Before use, the serum to be analyzed was heated to 56°C for 30 min and immediately cooled in an ice-water bath. To 0.1 ml of the heated test serum was added 0.1 ml of Veronal-buffered saline, pH 7.4, containing 0.005 M Veronal (Winthrop Laboratories, Sterling Drug Co., New York) and 0.1 M NaCl, followed by 100 ng 125I-Clq. This mixture was incubated at room temperature for 60 min and then at 40C for another 60 min. At the end of this incubation, polyethylene glycol (average mol wt 6,000) was added to a final volume of 2 ml in a final concentration of 2.5%. Incubation was at 40C for another 2 h. The tubes were then centrifuged at 2,000 g for 20 min. An equal volume of the upper half of the supernate (s fraction) was carefully transferred off, leaving precipitate and the remainder of the supemate (r fraction). The radioactivity of both fractions was counted in an automatic gamma counter. Clq-binding activity (Clq-BA) was calculated as percent of 125I-Clq precipitated according to the formula (r -s)l(r + s) x 100. All samples were tested in duplicate. Serum specimens from five normal subjects and two sera containing 100 and 500 ,g/ml of aggregated human gamma globulin were included in each test run. The coefficient of variation of the technique was 4.2 and 4.9% for specimens with mean values of Clq-BA of 25 and 48%, respectively, 25 replicate samples of each specimen being assayed.
The procedure was also performed, reacting 1251-Clq with varying amounts of heat-aggregated human gamma globulin. Aggregated human globulin was prepared from IgG purified by DEAE-chromatography and aggregated at 63°C for 20 min. The lower limit of sensitivy of the assay in terms of heat-aggregated human IgG was -75
,ug/ml. Additionally, to determine if DNA would interfere with the test, native DNA and single-stranded DNA were added in concentrations of 0.5-200 ,ug/ml to normal human serum with repetition of the assay. At those concentrations, increased 1251-Clq precipitation was not observed. Single-stranded DNA was prepared by heating DNA (calf thymus-Worthington Biochemical Corp., Freehold, N. J.) to 100°C for 10 min, followed by immediate cooling to 0°C in an ice-water bath. against 0.2 M glycine buffer, pH 3.2. All fractions were tested for the presence of IgG, IgM, and IgA by double diffusion or by radial immunodiffusion using monospecific antiserum to each immunoglobulin. The protein concentration of the pooled fractions containing complexes was 1-2 mg/ml.
Measurement of levels of complement components
Serum levels of Clq, C4, C3, properdin, and factor B were measured by radial immunodiffusion. The production of monospecific antiserum to each complement component has been previously described (11 For this procedure, a 0.2-ml aliquot of the reaction mixture between 125I-Clq and test sera prepared as above, and without the addition of polyethylene glycol, was layered on a 10-40% linear sucrose density gradient in Veronal-buffered saline, and centrifuged in a Spinco ultracentrifuge, model L2 (Beckman Instrument, Inc., Spinco Div., Palo Alto, Calif.), with an SW 50.1 rotor at 35,000 rpm for 24 h at 4°C. Fractions collected through a hole in the bottom of the tube were counted for radioactivity. Markers employed were human IgG (6.8S), human IgM (19S), human serum albumin (HSA, 4.6S), and catalase (11.2S). IgG, IgM, and HSA were measured by radial immunodiffusion and catalase by the disappearance of peroxide as measured spectrophotometrically at 240 nm.
Analysis of Clq binding complexes isolated by sucrose gradient analysis
Corresponding fractions obtained by repeated sucrose gradient analyses on a single serum specimen were pooled, dialyzed at 4°C against 0.05 M ammonium formate buffer, pH 7.4, lyophilized, and stored at -70°C until used. By this method, the complexes binding 1251-Clq contained in 1.2-1.5 ml of serum could be isolated. For analysis, the lyophilized pooled fractions were restored to a volume of 0.5 ml with neutral phosphate-buffered saline and dialyzed 
Clq-BA in serum samples
The Clq-BA of sera from normal subjects, patients undergoing rejection, and allografted patients in the quiescent period are shown in Fig. 1 10 patients whose renal histology showed only features of cellular rejection exhibited normal Clq-BA. Sera from nine patients whose renal biopsies showed evidence of fibrin deposition, and from five patients in whom no renal histology was available showed increased levels of Clq-BA ranging from 38 to 60%. These levels of Clq-BA correspond approximately to equivalent concentrations of 500-900 ,g/ml of aggregated human IgG. In comparison, the Clq-BA of sera from 11 allografted patients in the quiescent period was within normal limits.
Sequential measurements of serum Clq-BA 42 sera derived serially from eight patients with humoral rejection were also studied. The clinical course, measurements of serum Clq-BA, and various levels of complement components of two of these patients are shown in Fig. 2 (patient T. V.) and in Fig. 3  (patient B. G.) . In patient T. V. (Fig. 2) normal levels, parallel with the improvement of renal function. In patient B. G. (Fig. 3) , who experienced a protracted rejection episode, abnormal values for serum Clq-BA of 34 and 40% were obtained on days 5 and 8, respectively, the first abnormal value for serum Clq-BA antedating the diagnosis of clinical rejection by 4 days. Thereafter, despite treatment, renal functional impairment persisted, a biopsy during this period showing fibrin deposition in the glomerular capillaries together with mild cellular infiltration. Fluctuations of serum Clq-BA levels were noted, five of nine samples exhibiting increased levels of serum Clq-BA. By the 30th day, resolution of the rejection crisis occurred, concordant with a normal value for serum Clq-BA.
Serial assays of serum Clq-BA in the remaining six patients are shown in Fig. 4 . Increased values of serum Clq-BA were recorded in all patients during the period of rejection; with successful therapy, serum Clq-BA returned to within normal limits. Samples obtained from five patients soon after transplantation and before the onset of rejection showed normal serum Clq-BA; early samples were not available for the sixth patient.
Sequential studies of 12 sera from four patients undergoing cellular rejection showed normal Clq-BA for all specimens.
Complement studies
Serial studies in eight patients showed a relative fall of serum C3 levels at the time of humoral rejection. Less consistent relationships were obtained with serum Clq, C4, properdin, and factor B levels. By regression analysis, significant correlations were not obtained between levels of serum Clq-BA and levels of complement components measured. However, a significant correlation was derived between serum C4 and C3 levels (r = 0.62 P < 0.01).
Characteristics of Cl q-reactive complexes
Sucrose density gradient ultracentrifugation analysis of six Clq-reactive complexes from different patients showed them to have S values of 15S, 15.6S, 16 .8S, 17S, 18.1S, and 18.4S. Two representative analyses are depicted in Fig. 5 .
Analysis of the composition of the six complexes after acid dissociation (as described in Methods) showed them to contain IgG in all instances.
DISCUSSION
The rejection of a renal allograft involves both cellular and humoral mechanisms; morphologic studies have suggested that each mechanism may result in distinctive histopathologic features (12) . In predominantly cellular rejection, the principal change is one of infiltration of the tubulointerstitial structures with lymphocytes and other mononuclear cells; in humoral rejection, the dominant characteristic is the deposition of fibrin and microthrombi formation in the renal microvasculature (12) . It is recognized that overlap may frequently occur. The present study produced evidence that in the type of acute rejection characterized by fibrin deposition in the renal microvasculature, the responsible humoral mechanism may be the deposition of the circulating immune complexes. The presence of such complexes in the circulation was shown by a 1251-Clq binding assay, the sensitivity and reproducibility of which has been previously validated in other laboratories in studies of sera from patients with systemic lupus erythematosus, carriers of hepatitis-associated antigen (10), rheumatoid arthritis (13) , and by our studies of sera from patients with lupus nephritis, membranoproliferative glomerulonephritis, and other types of nephritides (14) . (2) (3) (4) .
Inferential evidence for the occurrence of an antigen-antibody reaction during a rejection crisis comes from measurements of serum levels of various complement components (17) (18) (19) (20) (21) . Although levels have been found to be unstable and fluctuating, various laboratories have documented a fall of the serum levels of the earlier components of complement, indicating activation of the classical pathway of complement. Our studies conform to this pattern, a fall of serum C3 levels occurring during rejection and a significant correlation being found between serum and C3 and C4 levels.
The induction of fibrin deposition in the microvasculature of the kidney in a process mediated by circulating immune complexes is not unusual, inasmuch as this is a finding in many types of glomerulonephritis. Positive interactions between antigenantibody complexes, complement, and the coagulation system have been identified and explored in several laboratory and animal models (22) . Of special relevance may be the animal model in which infusion of a small amount of antigen into a hyperimmunized animal produced acute cortical necrosis with extensive fibrin deposition (23) .
Finally, it is conceded that the current study demonstrates only an association between the presence of circulating immune complexes and the occurrence of rejection characterized by fibrin deposition in the kidney. Alternative theoretical possibilities are that immune complexes may represent bystander phenomena unrelated to the rejection process. It is also conceivable that the appearance of such complexes may be induced consequent to tissue damage by the rejection process or by therapy administered. There is, however, no evidence to suggest that steroid therapy will per se provoke the appearance of immune complexes. The role of ALG as an antigen appears to be excluded in at least four patients, two of whom were not given ALG, and in two others, in whom the episodes of rejection occurred temporally unrelated to ALG administration. The role of preexisting immune complexes also appears to be excluded in 10 patients with humoral rejection, in that their original kidney disease was of a "nonimmunologic" nature; confirmation was obtained from studies in 6 patients in whom assays of Clq-BA in the early period posttransplantation did not reveal the presence of circulating immune complexes. Further studies will be needed to elucidate the nature of the proximate antigen eliciting this sequence of events.
